| abstract |
The present invention particularly relates to a pharmaceutically acceptable composition comprising methylapol as the only pharmaceutically active substance; a composition comprising methylapol and at least one additional pharmaceutically active substance; the substance itself targeting the HPA axis is novel. A composition that is present or modified (eg, a bispecific antibody designed to permeate the blood brain barrier, or a known compound redesigned, eg, by conjugation to a substance that permeates the blood brain barrier); And a composition formulated so that the substance targeting the HPA axis does not significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to contain a dose that is too low to reduce plasma cortisol levels, or can be formulated to preferentially affect the skin. |